Vestcor Inc Has $273,000 Stake in Moderna, Inc. (NASDAQ:MRNA)

Vestcor Inc grew its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 15.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,569 shares of the company’s stock after buying an additional 855 shares during the period. Vestcor Inc’s holdings in Moderna were worth $273,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the stock. Rakuten Securities Inc. grew its holdings in Moderna by 696.9% during the fourth quarter. Rakuten Securities Inc. now owns 7,499 shares of the company’s stock valued at $312,000 after purchasing an additional 6,558 shares during the period. Avantax Advisory Services Inc. acquired a new position in shares of Moderna in the 4th quarter valued at $483,000. Farther Finance Advisors LLC increased its position in shares of Moderna by 289.3% in the 4th quarter. Farther Finance Advisors LLC now owns 3,519 shares of the company’s stock valued at $146,000 after buying an additional 2,615 shares in the last quarter. Moors & Cabot Inc. raised its stake in Moderna by 3.6% during the 4th quarter. Moors & Cabot Inc. now owns 56,423 shares of the company’s stock worth $2,346,000 after buying an additional 1,954 shares during the period. Finally, New Insight Wealth Advisors lifted its holdings in Moderna by 4.4% during the fourth quarter. New Insight Wealth Advisors now owns 8,545 shares of the company’s stock worth $355,000 after acquiring an additional 358 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Berenberg Bank increased their price target on Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a report on Thursday, January 16th. Leerink Partners dropped their target price on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a report on Thursday, January 16th. Barclays cut shares of Moderna from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $111.00 to $45.00 in a report on Tuesday, February 18th. JPMorgan Chase & Co. set a $45.00 price objective on shares of Moderna in a report on Friday, February 14th. Finally, Argus cut shares of Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Four research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $59.60.

Moderna Trading Up 0.3 %

Shares of MRNA opened at $34.71 on Tuesday. The company’s fifty day simple moving average is $35.78 and its 200 day simple moving average is $46.85. Moderna, Inc. has a 1-year low of $29.25 and a 1-year high of $170.47. The company has a market cap of $13.39 billion, a price-to-earnings ratio of -3.74 and a beta of 1.86.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.